1-6 of 6
Karen Clegg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Victoria Campbell, Harriet Walter, Adam Gibb, Andrew S. Davies, Nagah Elmusharaf, Neil Pegg, Will Henry West, Tomasz Knurowski, Kris Frese, Debbie Haynes, Karen Clegg, Tim Somervaille
Journal: Blood
Blood (2023) 142 (Supplement 1): 5795.
https://doi.org/10.1182/blood-2023-187378
Published: 2023
Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Emma Searle, James Cavet, Victoria Campbell, Steve Knapper, Ceri Bygrave, Dima El-Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet Walter, David Valcárcel, Marta Hidalgo Soto, Jenny O'Nions, Amrutha Sridhar, Tomasz Knurowski, Karen Clegg, Neil Pegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille
Journal: Blood
Blood (2023) 142 (Supplement 1): 2005.
https://doi.org/10.1182/blood-2023-174652
Published: 2023
Journal Articles

Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma

Luciano Nicosia, Nigel Brooks, Fabio Amaral, Oliver Sinclair, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, James Cavet, Emma Searle, Tim C.P Somervaille
Journal: Blood
Blood (2022) 140 (Supplement 1): 852–853.
https://doi.org/10.1182/blood-2022-157535
Published: 2022
Journal Articles

Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio Amaral, Naseer Basma, John Chadwick, Bradley Revell, Bettina Wingelhofer, Alba Maiques-Diaz, Filippo Ciceri, Daniel H Wiseman, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, Victoria Louise Campbell, Mhairi Copland, Emma Searle, Tim C.P Somervaille
Journal: Blood
Blood (2022) 140 (Supplement 1): 8774–8775.
https://doi.org/10.1182/blood-2022-166260
Published: 2022
Journal Articles

CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma

Nigel Brooks, Tomasz Knurowski, Andrew Hughes, Karen Clegg, William West, Neil A Pegg, Gary J Spencer, John Chadwick, Tim C.P Somervaille
Journal: Blood
Blood (2021) 138 (Supplement 1): 3291.
https://doi.org/10.1182/blood-2021-148295
Published: 2021
Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1266.
https://doi.org/10.1182/blood-2019-124797
Published: 2019